Browse > Article
http://dx.doi.org/10.24304/kjcp.2019.29.4.254

Clinical Outcomes of Antiplatelets Combined with Statins in Patients with Ischemic Heart Disease  

Kim, Chungsoo (Department of Biomedical Science, Graduate School of Medicine, Ajou University)
Lee, Jimin (College of Pharmacy, Ajou University)
Park, Rae Woong (Department of Biomedical Science, Graduate School of Medicine, Ajou University)
Lee, Sukhyang (College of Pharmacy, Ajou University)
Publication Information
Korean Journal of Clinical Pharmacy / v.29, no.4, 2019 , pp. 254-266 More about this Journal
Abstract
Background: Patients with cardiovascular risks are recommended to use statins and antiplatelet agents to prevent major cerebro-cardiovascular events (MACCE). Antiplatelet agents also possess anti-inflammatory and antioxidant effects, in addition to their inhibitory activity on platelets. The differences in clinical outcomes in ischemic heart disease (IHD) based on the type of antiplatelet therapy combined with statin treatment were investigated in this study. Methods: We conducted a retrospective cohort study using electronic medical records of IHD patients from January 2010 to December 2014 at Ajou University Hospital. Patients on combination therapy of antiplatelet drugs and statins were grouped based on antiplatelet drug types: clopidogrel, cilostazol, or sarpogrelate. Propensity score matching was applied to balance the baseline of the groups of clopidogrel vs. cilostazol and the groups of clopidogrel vs. sarpogrelate. The incidence and risk of MACCE as primary outcomes were assessed between the groups of antiplatelet drugs. Results: Among the approximately 128,500 patients with IHD, 1,049 patients had taken a combination therapy of statin and antiplatelet agents. The cohorts of patients administered clopidogrel, cilostazol, or sarpogrelate were 906, 79, and 64, respectively. The incidence of MACCE was not significantly different among the cohorts (p=0.58), and there were no differences between clopidogrel vs. cilostazol (p=0.72) or clopidogrel vs. sarpogrelate (p=1.00) after propensity score matching. Conclusion: There was no difference in the incidence of MACCE based on the type of antiplatelet drug (clopidogrel, cilostazol, or sarpogrelate) in combination with a statin in patients with IHD.
Keywords
Major adverse cerebro-cardiovascular events (MACCE); statin; clopidogrel; cilostazol; sarpogrelate; real world data;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kim IS, Jeong YH, Park Y, et al. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol 2012;73:629-40.   DOI
2 Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9.   DOI
3 Hafez HM, Ibrahim MA, Zedan MZ, Hassan M, Hassanein H. Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/ NQO-1 signaling pathway. Toxicol Mech Methods 2019;29:146-52.   DOI
4 Noh Y, Lee J, Shin S, et al. Effects of cilostazol and reninangiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study. Int J Clin Pharm 2018;40:160-8.   DOI
5 Park JH, Choi BH, Ku SK, et al. Amelioration of high fat dietinduced nephropathy by cilostazol and rosuvastatin. Arch Pharm Res 2017;40:391-402.   DOI
6 Tang WH, Lin FH, Lee CH, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014;45:293-301.   DOI
7 Park, K-Y, Heo, T-H. Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice. Cardiovasc Ther. 2018;36:e12476.   DOI
8 Kim SR, Choi KH, Song YB, et al. Effect of sarpogrelate and highdose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study. Clin Cardiol 2019:10.1002/clc.23239. [Epub ahead of print.]
9 Nomura S, Taniura T, Shouzu A, et al. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliteransrelated biomarkers in patients with type 2 diabetes (SAREPITASO study). Vasc Health Risk Manag 2018;14:225-32.   DOI
10 Yoo H, Park I, Kim DJ, Lee S. Effects of sarpogrelate on microvascular complications with type 2 diabetes. Int J Clin Pharm 2019;41:563-73.   DOI
11 Health Insurance Review Assessment Service. Healthcare Bigdata hub. Available from http://opendata.hira.or.kr/op/opc/olapHifrqSickInfo.do. Accessed August 12, 2019.
12 Grundy SM and Stone NJ. 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the management of blood cholesterol: primary prevention. JAMA Cardiol 2019; 4(5):488-9.   DOI
13 Grundy SM and Stone NJ. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the management of blood cholesterol-secondary prevention. JAMA Cardiol 2019; 4(6):589-91.   DOI
14 Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e89S-e119S.   DOI
15 Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082-115.   DOI
16 Johansen ME, Hefner JL, Foraker RE. Antiplatelet and statin use in US patients With coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol 2015;115:1507-12.   DOI
17 Ye K, Kim JT, Lee S. Effect of triple compared to dual antiplatelet therapy after drug-eluting stent implantation in percutaneous coronary intervention 2012;22:113-22.
18 Noh Y, Lee J, Shin S, et al. Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the Korean national health insurance claim database. PLoS One 2016;11:e0150475.   DOI
19 Nakao T, Kimura T, Morimoto T, et al. The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimuseluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry. Cardiovasc Interv Ther 2012;27:161-7.   DOI
20 Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009;134:351-5.   DOI
21 Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007;71:1867-72.   DOI
22 Aoki C, Hattori Y, Tomizawa A, Jojima T, Kasai K. Antiinflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb 2010;17:503-9.   DOI
23 Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-42.   DOI
24 Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clin J Am Soc Nephrol 2008;3:362-8.   DOI
25 Jeong IS, Park JH, Jin SA, et al. Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers. Heart Vessels 2013;28:578-82.   DOI
26 Hidaka S, Kobayashi S, Iwagami M, et al. Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Ren Fail 2013;35:43-8.   DOI
27 Murphy B and Fraeman KH. A general SAS(R) macro to implement optimal N: 1 propensity score matching within a maximum radius 2017:13.
28 Fraeman K. An introduction to implementing propensity score matching with $SAS^{(R)}$ 2010. Available from https://www.researchgate.net/publication/306159704_An_introduction_to_implementing _propensity_score_matching_with_SAS. Accessed August 12, 2019.
29 Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019 Aug 31. pii: ehz425. doi: 10.1093/eurheartj/ehz425. [Epub ahead of print].